Australia’s expedited plan to start dishing out COVID jabs in mid-late February will call for NASA-like logistical organisation. And ideally, no more clusters of infections to distract frontline workers.
Academic rigour, journalistic flair
Articles on Pfizer-BioNTech vaccine
Displaying 121 - 140 of 148 articles
With vaccines forthcoming for most Americans, many groups, including expectant mothers, are wondering if the vaccine is safe for them and their babies. A physician-scientist explains.
A new strain of the SARS-CoV-2 virus that causes COVID-19 appears to be spreading fast in the UK. This probably isn’t a big problem, but the data isn’t in yet.
A serious allergic reaction was reported in a health care worker in Alaska after she received the COVID-19 vaccine. Does this mean that people with allergies need to be concerned? An expert answers.
Experts from across The Conversation assess the work that’s helped us reach vaccine roll-out, how this could play out, and the risk of vaccine hesitancy.
The development of multiple vaccines against the virus that causes COVID-19 has been hailed as the breakthrough of 2020. But there were many more supporting discoveries that made this possible.
Here’s what we still need to find out before we can know when we’ll be able to return to our pre-coronavirus ways.
As the coronavirus rages, a vaccine finally is available for certain groups of people and will soon be ready for other groups. But there are plenty of questions. A doctor answers five here.
We still need to know exactly what part of the immune response offers protection – and how strong it needs to be to remain protective.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
Reports of two UK health workers having allergic reactions after receiving Pfizer’s COVID vaccine have led to safety warnings for others at risk of anaphylaxis.
If supplies of COVID-19 vaccine are initially limited, who should be vaccinated first? A mathematical model shows when and why it’s best to start with the young, and when older people should go first.
COVID-19 vaccine testing on children is just getting started, and only in adolescents.
The all important ‘last-mile’ logistics.
Vaccine hesitancy is not new, but it has a new element: few people can remember the devastating impact of diseases such as smallpox and polio and it is hard to see the lives saved by vaccination.
Millions of Britons will be given a COVID vaccination card proving they have received the jab.
Logistics is the unsung hero in vaccination. But here’s why it’s critical.
It may be many months before COVID control measures can be eased.
With COVID-19 vaccine announcements making headlines, non-scientists need to know what clinical trial results mean. Here are some key points to look for in vaccine trial reports.
There is now a third vaccine that prevents COVID-19 infections. It isn’t quite as effective as the other two vaccines but it has advantages that may make it the frontrunner.
Top contributors
-
Professor of Medicine, University of Virginia
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Associate Professor of Pediatrics, University of Virginia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Chair in Epidemiology, Deakin University
-
Instructor of Human Immunology, Emory University
-
Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Deputy Director of the HUMLOG (Humanitarian Logistics and Supply Chain Management Research) Institute, Hanken School of Economics
-
Associate Professor in Viral Immunology, University of Birmingham
-
Director of the Digital Health Enterprise Zone (DHEZ), University of Bradford, Professor of Health Service Operations, University of Bradford
